Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 14/20 | 0.72 |
| ▸ | CDK8 | P49336 | 14/20 | 0.72 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486028 | 1.00 | CCNC (0.72) | CCNCCDK8CDK19NPC1TP53 | |
| SCHEMBL4826674 | 0.92 | CCNC (0.61) | CCNCCDK8CDK19NPC1TP53 | |
| SCHEMBL4826684 | 0.92 | CCNC (0.61) | CCNCCDK8CDK19NPC1TP53 | |
| SCHEMBL4833159 | 0.86 | CCNC (0.54) | CCNCCDK8CDK19NPC1TP53 | |
| SCHEMBL4833145 | 0.86 | CCNC (0.54) | CCNCCDK8CDK19NPC1TP53 | |
| SCHEMBL4834390 | 0.86 | CCNC (0.53) | CCNCCDK8CDK19NPC1TP53 | |
| SCHEMBL4834408 | 0.86 | CCNC (0.53) | CCNCCDK8CDK19NPC1TP53 | |
| SCHEMBL4836714 | 0.84 | CCNC (0.51) | CCNCCDK8CDK19NPC1TP53 | |
| SCHEMBL4836704 | 0.84 | CCNC (0.51) | CCNCCDK8CDK19NPC1TP53 | |
| SCHEMBL14874648 | 0.83 | CCNC (1.00) | CCNCCDK8CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029724-A1 | SCREENING METHOD | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-02-04 | — | — | US | disclosed |
| EP-2039779-A1 | SCREENING METHOD | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029724-A1 | SCREENING METHOD | NR2C2, NCOR2, NCOA2 | CCNC 3143/4885CDK8 2999/4885CDK19 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.